Peñas-Lledó EM - Search Results

1

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

Dorado P, Berecz R, Peñas-Lledó EM, Cáceres MC, Llerena A. Dorado P, et al. Curr Drug Targets. 2006 Dec;7(12):1671-80. doi: 10.2174/138945006779025329. Curr Drug Targets. 2006. PMID: 17168842 Review.

2

[Prevalence of polydipsia and water intoxication in psychiatric inpatients].

Llerena A, De la Rubia Martínez A, Peñas-Lledó EM. Llerena A, et al. Actas Esp Psiquiatr. 2001 Sep-Oct;29(5):299-303. Actas Esp Psiquiatr. 2001. PMID: 11602086 Spanish.

3

Schizophrenia stigma among medical and nursing undergraduates.

Llerena A, Cáceres MC, Peñas-LLedó EM. Llerena A, et al. Eur Psychiatry. 2002 Sep;17(5):298-9. doi: 10.1016/s0924-9338(02)00672-7. Eur Psychiatry. 2002. PMID: 12381503 No abstract available.

4

Schizophrenia and tobacco smoking in a Spanish psychiatric hospital.

LLerena A, de la Rubia A, Peñas-Lledó EM, Diaz FJ, de Leon J. LLerena A, et al. Schizophr Res. 2003 Apr 1;60(2-3):313-7. doi: 10.1016/s0920-9964(02)00508-x. Schizophr Res. 2003. PMID: 12591592

5

CYP2C9 gene and susceptibility to major depressive disorder.

LLerena A, Berecz R, Dorado P, González AP, Peñas-LLedó EM, De La Rubia A. LLerena A, et al. Pharmacogenomics J. 2003;3(5):300-2. doi: 10.1038/sj.tpj.6500197. Pharmacogenomics J. 2003. PMID: 14583800

6

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM. LLerena A, et al. Eur J Clin Pharmacol. 2004 Feb;59(12):869-73. doi: 10.1007/s00228-003-0707-y. Epub 2004 Jan 16. Eur J Clin Pharmacol. 2004. PMID: 14726986 Clinical Trial.

7

Reduced completed suicide rate in Hungary from 1990 to 2001: relation to suicide methods.

Berecz R, Cáceres M, Szlivka A, Dorado P, Bartók E, Peñas-LLedó E, LLerena A, Degrell I. Berecz R, et al. J Affect Disord. 2005 Oct;88(2):235-8. doi: 10.1016/j.jad.2005.07.005. J Affect Disord. 2005. PMID: 16122812

8

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Dorado P, et al. Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):9-19. doi: 10.1517/17425255.3.1.9. Expert Opin Drug Metab Toxicol. 2007. PMID: 17269891 Review.

9

Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.

Llerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A. Llerena A, et al. Pharmacogenomics J. 2007 Dec;7(6):408-10. doi: 10.1038/sj.tpj.6500439. Epub 2007 Feb 27. Pharmacogenomics J. 2007. PMID: 17325735

10

No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.

Dorado P, Berecz R, Peñas-Lledó EM, de la Rubia A, Llerena A. Dorado P, et al. Eur J Clin Pharmacol. 2007 May;63(5):527-8. doi: 10.1007/s00228-007-0284-6. Epub 2007 Mar 8. Eur J Clin Pharmacol. 2007. PMID: 17345072 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters